The Wistar Institute

2019–2024 · research · R01

Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder

Luis J Montaner · The Wistar Institute · funded by National Institutes of Health

$827.9kHIV Research and Treatment

2019–2025 · research · R01

Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment

David S Metzger · The Wistar Institute · funded by National Institutes of Health

$1.6M

2019–2024 · research · R01

Stress Response Functions of ADAR1 Regulated by MAP Kinases

Kazuko Nishikura · The Wistar Institute · funded by National Institutes of Health

$375.1kRNA regulation and disease

2019–2024 · research · R01

The impact of coding region variants on mutant p53 biology

Maureen E. Murphy · The Wistar Institute · funded by National Institutes of Health

$484.1kCancer-related Molecular Pathways

2019–2025 · research · R01

Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection

David B. Weiner · The Wistar Institute · funded by National Institutes of Health

$979.2k

2019–2023 · research · R01

Role of an Integrator-EGR axis in the regulation of myeloid enhancers

Alessandro Gardini · The Wistar Institute · funded by National Institutes of Health

$446.5kImmune cells in cancer

2019–2024 · research · R01

Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder

Luis J Montaner · The Wistar Institute · funded by National Institutes of Health

$764.9kHIV Research and Treatment

2019–2024 · research · R01

Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment

David S Metzger · The Wistar Institute · funded by National Institutes of Health

$1.7M

2019–2023 · research · R01

Role of an Integrator-EGR axis in the regulation of myeloid enhancers

Alessandro Gardini · The Wistar Institute · funded by National Institutes of Health

$577.6kImmune cells in cancer

2019–2024 · research · R01

Glycomic Modulation of Gut Microbiome During HIV Infection

Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health

$806.6k

2019–2022 · program · P01

Project 3 - Mitochondrial regulation of the immunosuppressive prostate cancer microenvironment

Marcelo G. Kazanietz · The Wistar Institute · funded by National Institutes of Health

2018–2021 · grant · PCRP

A First-in-Human, Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib, in Advanced and Metastatic Prostate Cancer

Dario Altieri · The Wistar Institute · funded by Congressionally Directed Medical Research Programs

$905.4k

2018–2024 · research · R01

Regulation of Viral Chromatin Architecture During EBV Latency

Italo Tempera · The Wistar Institute · funded by National Institutes of Health

$457.6kViral-associated cancers and disorders

2018–2029 · research · R01

Regulation of Viral Chromatin Architecture During EBV Latency

Italo Tempera · The Wistar Institute · funded by National Institutes of Health

$542kViral-associated cancers and disorders

2018–2023 · research · R01

Regulation of Viral Chromatin Architecture During EBV Latency

Italo Tempera · The Wistar Institute · funded by National Institutes of Health

$457.6kViral-associated cancers and disorders

2018–2019 · fellowship · F32

Tumor Suppression by an African Specific Variant of p53

Thibaut Barnoud · The Wistar Institute · funded by National Institutes of Health

$54.9kFerroptosis and cancer prognosis

2018–2022 · research · R01

Regulation and Functions of 3'UTRs in Cellular Stress

Bin Tian · The Wistar Institute · funded by National Institutes of Health

$236.9k

2018–2019 · research · R01

TARGETING ANTIGEN-INDUCED ER STRESS RESPONSE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEM

Chih-Chi Andrew Hu · The Wistar Institute · funded by National Institutes of Health

$53.5kEndoplasmic Reticulum Stress and Disease

2018–2019 · research · R21

The role of p53 in Iron Overload

Maureen E. Murphy · The Wistar Institute · funded by National Institutes of Health

$150.2kIron Metabolism and Disorders

2018–2019 · research · R01

Mechanism of myeloid cell defect in cancer

Dmitry I Gabrilovich · The Wistar Institute · funded by National Institutes of Health

$178.2kImmune cells in cancer

2018–2023 · grant · OCRP

Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-A inhibitor, ipilimumab in platinum resistant ovarian cancer

Alessandro Gardini · The Wistar Institute · funded by Congressionally Directed Medical Research Programs

$1.1M

2018–2023 · research · R01

Regulation of Viral Chromatin Architecture During EBV Latency

Italo Tempera · The Wistar Institute · funded by National Institutes of Health

$457.6kViral-associated cancers and disorders

2018–2023 · research · R01

Regulation and Functions of 3'UTRs in Cellular Stress

Bin Tian · The Wistar Institute · funded by National Institutes of Health

$365k

2018–2022 · research · R01

Regulation and Functions of 3'UTRs in Cellular Stress

Bin Tian · The Wistar Institute · funded by National Institutes of Health

$365k

2018–2019 · fellowship · F32

Tumor Suppression by an African Specific Variant of p53

Thibaut Barnoud · The Wistar Institute · funded by National Institutes of Health

$59kFerroptosis and cancer prognosis

2018 · fellowship · AACR-AstraZeneca Ovarian Cancer Research Fellowship

EZH2 inhibition sensitizes CARM1-positive ovarian cancer to PARP inhibitors

Sergey Karakashev · The Wistar Institute · funded by American Association for Cancer Research

2018–2029 · research · R01

Regulation of Viral Chromatin Architecture During EBV Latency

Italo Tempera · The Wistar Institute · funded by National Institutes of Health

$542k

2017–2019 · research · R21

Role of Host Glycosylation in the Galectin-9-Mediated Reversal of HIV Latency

Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health

$212.9kGalectins and Cancer Biology

2017–2022 · research · R01

Regulation of PRC2 functions by PARP1

Italo Tempera · The Wistar Institute · funded by National Institutes of Health

$383.3kPARP inhibition in cancer therapy

2017–2023 · cooperative agreement · U54

Rational approaches to melanoma therapy

Michael Davies · The Wistar Institute · funded by National Institutes of Health

$589.7k

2017–2018 · career development · K99

Oncogenic Disruption of the Circadian Metabolic Cycle in Cancer

Brian James Altman · The Wistar Institute · funded by National Institutes of Health

$86.5k

2017–2022 · research · R01

Multivalent DNA vaccine-mediated protection against Tuberculosis

David B. Weiner · The Wistar Institute · funded by National Institutes of Health

$370.4kTuberculosis Research and Epidemiology

2017–2020 · fellowship · F32

Targeting hyaluronan in the tumor microenvironment to improve DNA vaccine immunotherapy

Elizabeth Kennedy Duperret · The Wistar Institute · funded by National Institutes of Health

$56.7kProteoglycans and glycosaminoglycans research

2017–2018 · grant · S10

Purchase of a PerkinElmer IVIS SpectrumCT Imaging System

Paul M. Lieberman · The Wistar Institute · funded by National Institutes of Health

$579.3k

2017–2022 · research · R01

Negative regulation of myeloid-derived suppressive cells in cancer

Serge Y Fuchs · The Wistar Institute · funded by National Institutes of Health

$26.8kImmune cells in cancer

2017–2022 · research · R50

Advancing Cancer Research through Comprehensive Proteomics and Metabolomics Analyses

Hsin-Yao Tang · The Wistar Institute · funded by National Institutes of Health

$188.5k

2017–2022 · research · R01

Negative regulation of myeloid-derived suppressive cells in cancer

Serge Y Fuchs · The Wistar Institute · funded by National Institutes of Health

$493.7kImmune cells in cancer

2017–2020 · research · Global Health

Wistar Institute of Anatomy & Biology - to develop new synthetic DNA vaccines encoding designed CSP antigens to provide a new generation advanced CSP component for a prophylactic malaria ...

The Wistar Institute · funded by Bill and Melinda Gates Foundation

$1MMalaria Research and Control

2017–2022 · research · R01

Negative regulation of myeloid-derived suppressive cells in cancer

Serge Y Fuchs · The Wistar Institute · funded by National Institutes of Health

$471.2kImmune cells in cancer

2017–2022 · research · R50

Advancing Cancer Research through Comprehensive Proteomics and Metabolomics Analyses

Hsin-Yao Tang · The Wistar Institute · funded by National Institutes of Health

$188.5k